The Efficacy and Immunogenicity of COVID-19 Vaccine: Special Focus on Patients with Cancer-Scilight

Trends in Immunotherapy

Review

The Efficacy and Immunogenicity of COVID-19 Vaccine: Special Focus on Patients with Cancer

Downloads

https://doi.org/10.54963/ti.v9i3.1017
Israilova Zeinep Abdukalykovna, Alhamza Abdulsatar Shaker, Sanarya Thamer Naser, Ahmed M. Hussein, Thamer Al‑Hilfi, & Fakher Rahim. (2025). The Efficacy and Immunogenicity of COVID-19 Vaccine: Special Focus on Patients with Cancer. Trends in Immunotherapy, 9(3), 15–29. https://doi.org/10.54963/ti.v9i3.1017
Volume 9 Issue 3 (September 2025) (in progress)
Copyright (c) 2025 Israilova Zeinep Abdukalykovna, Alhamza Abdulsatar Shaker, Sanarya Thamer Naser, Ahmed M. Hussein, Thamer Al‑Hilϐi, Fakher Rahim
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Israilova Zeinep Abdukalykovna

    International Medical Faculty, Osh State University, Osh 723500, Kyrgyzstan
  • Alhamza Abdulsatar Shaker

    Department of Medical Laboratory Analysis, Al Mansour University College, Baghdad 10067, Iraq
  • Sanarya Thamer Naser

    Department of Medical Laboratory Analysis, Al‑Turath University, Baghdad 10013, Iraq
  • Ahmed M. Hussein

    Department of Medical Laboratory Analysis, Al‑Raϐidain University College, Baghdad 10064, Iraq
  • Thamer Al‑Hilfi

    Department of Medical Laboratory Analysis, Madenat Alelem University College, Baghdad 10006, Iraq
  • Fakher Rahim

    Department of Internal Medicine, Osh State University, Osh 723500, Kyrgyzstan

Received: 13 February 2025; Revised: 13 March 2025; Accepted: 14 March 2025; Published: 21 July 2025

Research indicates that immunization is the most efficacious approach for stopping the transmission of COVID-19. This study aims to offer immunization recommendations for patients with autoimmune/autoinflammatory rheumatological disorders, immunodeficiencies, cancer, diabetes, chronic respiratory, and cardiovascular diseases. The intended audience includes doctors, medical personnel, and patients. This review study involved conducting a search in scholarly electronic databases, including ISI, Google Scholar, Scopus, and PubMed. The issue of COVID-19 vaccinations and the vaccination of patients with certain disorders was informed by the latest and pertinent authoritative publications published between 1980 and 2024. When autoimmune illness patients effectively manage their disease activity and there is no concurrent infection, they should receive the COVID-19 vaccination. Low-intensity immunosuppression does not reduce the antibody response to vaccinations. Immunization using all forms of vaccination, excluding live attenuated vaccines, is efficacious for all individuals with cancer, except for those undergoing anti-B cell therapy. Additionally, it is recommended to administer vaccinations to individuals who have underlying conditions such as obesity, cardiovascular diseases, respiratory diseases, and diabetes, as these conditions heighten the chance of developing severe cases of COVID-19. To combat the COVID-19 virus, the most effective approach is to increase vaccination coverage in order to stimulate immune responses. This paper provides a thorough examination of the latest developments and existing challenges in the area of COVID-19 vaccines against cancer. Additionally, it explores the prospective future uses of vaccines in cancer immunotherapies.

Keywords:

SARS‑CoV‑2 Virus; COVID‑19; Vaccination; Vaccine Efϐicacy; mRNA Vaccine; Cancer

References

  1. Khakimova, A.; Abdollahi, L.; Zolotarev, O.; et al. Global interest in vaccines during the COVID-19 pandemic: Evidence from Google Trends. Vaccine X 2022, 10, 100152.
  2. Zhang, G.; Tang, T.; Chen, Y.; et al. mRNA Vaccines in Disease Prevention and Treatment. Signal Transduct. Target. Ther. 2023, 8, 365.
  3. Fang, E.; Liu, X.; Li, M.; et al. Advances in COVID-19 mRNA Vaccine Development. Signal Transduct. Target. Ther. 2022, 7, 94.
  4. Adjiri, A. Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncol. Ther. 2016, 4, 17–33.
  5. Donninger, H.; Li, C.; Eaton, J.W.; et al. Cancer Vaccines: Promising Therapeutics or an Unattainable Dream. Vaccines (Basel) 2021, 9, 668.
  6. Blumberg, B.S. Hepatitis B Virus, the Vaccine, and the Control of Primary Cancer of the Liver. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 7121–7125.
  7. Hampson, I.N. Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology. Viruses 2022, 14, 757.
  8. Tsao, S.Y. Potential of mRNA Vaccines to Become Versatile Cancer Vaccines. World J. Clin. Oncol. 2022, 13, 663–674.
  9. Wang, B.; Pei, J.; Xu, S.; et al. Recent Advances in mRNA Cancer Vaccines: Meeting Challenges and Embracing Opportunities. Front. Immunol. 2023, 14, 1246682.
  10. Katopodi, T.; Petanidis, S.; Grigoriadou, E.; et al. Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into Tumor Editing Therapy. Pharmaceutics 2024, 16, 455.
  11. Karam, M.; Daoud, G. mRNA Vaccines: Past, Present, future. Asian J. Pharm. Sci. 2022, 17, 491–522.
  12. Kaczmarek, J.C.; Kowalski, P.S.; Anderson, D.G. Advances in the Delivery of RNA Therapeutics: from Concept to Clinical Reality. Genome Med. 2017, 9, 60.
  13. Zhu, G.; Zhang, F.; Ni, Q.; et al. Efficient Nanovaccine Delivery in Cancer Immunotherapy. ACS Nano 2017, 11, 2387–2392.
  14. Blakney, A.K.; Zhu, Y.; McKay, P.F.; et al. Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer. ACS Nano 2020, 14, 5711–5727.
  15. Corbett, K.S.; Edwards, D.K.; Leist, S.R.; et al. SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness. Nature 2020, 586, 567–571.
  16. Corbett, K.S.; Flynn, B.; Foulds, K.E.; et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. 2020, 383, 1544–1555.
  17. Tai, W.; Zhang, X.; Drelich, A.; et al. A Novel Receptor-Binding Domain (RBD)-Based mRNA Vaccine against SARS-CoV-2. Cell Res. 2020, 30, 932–935.
  18. Velusamy, P.; Kiruba, K.; Su, C.H.; et al. SARS-CoV-2 Spike protein: Site-Specific Breakpoints for the Development of COVID-19 Vaccines. J. King Saud Univ. Sci. 2021, 33, 101648.
  19. Acosta-Coley, I.; Cervantes-Ceballos, L.; Tejeda-Benítez, L.; et al. Vaccines Platforms and COVID-19: What You Need to Know. Trop Dis. Travel Med. Vaccines 2022, 8, 20.
  20. Kashte, S.; Gulbake, A.; El-Amin Iii, S.F.; et al. COVID-19 Vaccines: Rapid Development, Implications, Challenges and Future Prospects. Hum. Cell 2021, 34, 711–733.
  21. Excler, J.-L.; Saville, M.; Berkley, S.; et al. Vaccine Development for Emerging Infectious Diseases. Nat. Med. 2021, 27, 591–600.
  22. Ndwandwe, D.; Wiysonge, C.S. COVID-19 Vaccines. Curr. Opin. Immunol. 2021, 71, 111–116.
  23. Yarlagadda, H.; Patel, M.A.; Gupta, V.; et al. COVID-19 Vaccine Challenges in Developing and Developed Countries. Cureus 2022, 14, e23951.
  24. Hopkins, K.L.; Underwood, T.; Iddrisu, I.; et al. Community-Based Approaches to Increase COVID-19 Vaccine Uptake and Demand: Lessons Learned from Four UNICEF-Supported Interventions. Vaccines (Basel) 2023, 11, 1180.
  25. Lazarus, J.V.; Wyka, K.; White, T.M.; et al. A Survey of COVID-19 Vaccine Acceptance across 23 Countries in 2022. Nat. Med. 2023, 29, 366–375.
  26. Falsey, A.R.; Sobieszczyk, M.E.; Hirsch, I.; et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N. Engl. J. Med. 2021, 385, 2348–2360.
  27. Halperin, S.A.; Ye, L.; MacKinnon-Cameron, D.; et al. Final Efficacy Analysis, Interim Safety Analysis, and Immunogenicity of a Single dose of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years and Older: An International, Multicentre, Randomised, Double-Blinded, Placebo-Controlled Phase 3 Trial. Lancet 2022, 399, 237–248.
  28. Sadoff, J.; Gray, G.; Vandebosch, A.; et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N. Engl. J. Med. 2022, 386, 847–860.
  29. Logunov, D.Y.; Dolzhikova, I.V.; Shcheblyakov, D.V.; et al. Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia. Lancet 2021, 397, 671–681.
  30. Kraynyak, K.A.; Blackwood, E.; Agnes, J.; et al. SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial. J. Infect. Dis. 2022, 225, 1923–1932.
  31. Kow, C.S.C.; Ramachandram, D.S.; Hasan, S.S. The Effectiveness of BNT162b2 mRNA Vaccine against COVID-19 Caused by Delta Variant of SARS-CoV-2: A Systematic Review and Meta-Analysis. Inflammopharmacology 2022, 30, 149–157.
  32. Baden, L.R.; El Sahly, H.M.; Essink, B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384, 403–416.
  33. Kelton, J.G.; Arnold, D.M.; Nazy, I. Lessons from Vaccine-Induced Immune Thrombotic Thrombocytopenia. Nat. Rev. Immunol. 2021, 21, 753–755.
  34. Dabbiru, V.A.S.; Müller, L.; Schönborn, L.; et al. Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)-Insights from Clinical Cases, In Vitro Studies and Murine Models. J. Clin. Med. 2023, 12, 6126.
  35. Allas, G.D.O.; Arizala, J.D.R.; Manalo, R.V.M. COVID-19 Adenoviral Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), COVID-19-Related Thrombosis, and the Thrombotic Thrombocytopenic Syndromes. Hematol. Rep. 2022, 14, 358–372.
  36. Tsang, R.S.; Agrawal, U.; Joy, M.; et al. Adverse Events after First and Second Doses of COVID-19 Vaccination in England: A National Vaccine Surveillance Platform Self-Controlled Case Series Study. J. R. Soc. Med. 2024, 117, 134–148.
  37. Copland, E.; Patone, M.; Saatci, D.; et al. Safety Outcomes Following COVID-19 Vaccination and Infection in 5.1 Million Children in England. Nat. Commun. 2024, 15, 3822.
  38. Lapuente, D.; Winkler, T.H.; Tenbusch, M. B-cell and Antibody Responses to SARS-CoV-2: Infection, Vaccination, and Hybrid Immunity. Cell. Mol. Immunol. 2024, 21, 144–158.
  39. Yu, E.D.; Narowski, T.M.; Wang, E.; et al. Immunological Memory to Common Cold Coronaviruses Assessed Longitudinally over a Three-Year Period Pre-COVID19 Pandemic. Cell Host Microbe 2022, 30, 1269–1278.
  40. Siles, N.; Schuler, M.; Maguire, C.; et al. SARS-CoV-2 Humoral Immune Responses in Convalescent Individuals Over 12 Months Reveal Severity-Dependent Antibody Dynamics. medRxiv [Preprint] 2023. DOI: https://doi.org/10.1101/2023.12.05.23299462
  41. Kotsiou, O.S.; Karakousis, N.; Papagiannis, D.; et al. The Comparative Superiority of SARS-CoV-2 Antibody Response in Different Immunization Scenarios. J. Pers. Med. 2022, 12, 1756.
  42. Hvidt, A.K.; Baerends, E.A.M.; Søgaard, O.S.; et al. Comparison of Vaccine-Induced Antibody Neutralization against SARS-CoV-2 Variants of Concern Following Primary and Booster Doses of COVID-19 Vaccines. Front. Med. (Lausanne) 2022, 9, 994160.
  43. Muecksch, F.; Wise, H.; Templeton, K.; et al. Longitudinal Variation in SARS-CoV-2 Antibody levels and Emergence of Viral Variants: A Serological Analysis. Lancet Microbe 2022, 3, e493–e502.
  44. Piano Mortari, E.; Russo, C.; Vinci, M.R.; et al. Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA. Cells 2021, 10, 2541.
  45. Hall, V.J.; Insalata, F.; Foulkes, S.; et al. Effectiveness of BNT162b2 mRNA Vaccine Third Doses and Previous Infection in Protecting against SARS-CoV-2 Infections during the Delta and Omicron Variant Waves; the UK SIREN Cohort Study September 2021 to February 2022. J. Infect. 2024, 88, 30–40.
  46. Jara, A.; Undurraga, E.A.; Zubizarreta, J.R.; et al. Effectiveness of Homologous and Heterologous Booster doses for an Inactivated SARS-CoV-2 Vaccine: A Large-Scale Prospective Cohort Study. Lancet Glob. Health 2022, 10, e798–e806.
  47. Asano, M.; Okada, H.; Itoh, Y.; et al. Immunogenicity and Safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a Double-Blind, Randomized Controlled Phase 1/2 Trial. Int. J. Infect. Dis. 2022, 114, 165–174.
  48. Swanson, P.A.; Padilla, M.; Hoyland, W.; et al. T-Cell Mediated Immunity after AZD1222 Vaccination: A Polyfunctional Spike-Specific Th1 Response with a Diverse TCR Repertoire. [Preprint] 2021.
  49. Zhang, Z.; Wu, S.; Liu, Y.; et al. Boosting with an Aerosolized Ad5-nCoV Elicited Robust Immune Responses in Inactivated COVID-19 Vaccines Recipients. Front. Immunol. 2023, 14, 1239179.
  50. Zhang, H.; Xu, N.; Xu, Y.; et al. Safety and Immunogenicity of Ad5-nCoV Immunization after Three-Dose Priming with Inactivated SARS-CoV-2 Vaccine in Chinese Adults. Nat. Commun. 2023, 14, 4757.
  51. Barouch, D.H.; Stephenson, K.E.; Sadoff, J.; et al. Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19. [Preprint] 2021.
  52. Cornejo, A.; Franco, C.; Rodriguez-Nuñez, M.; et al. Humoral Immunity across the SARS-CoV-2 Spike after Sputnik V (Gam-COVID-Vac) Vaccination. Antibodies 2024, 13, 41.
  53. Martynova, E.; Hamza, S.; Garanina, E.E.; et al. Long Term Immune Response Produced by the SputnikV Vaccine. Int. J. Mol. Sci. 2021, 22, 11211.
  54. Walters, J.N.; Schouest, B.; Patel, A.; et al. Prime-Boost Vaccination Regimens with INO-4800 and INO-4802 Augment and Broaden Immune Responses against SARS-CoV-2 in Nonhuman Primates. Vaccine 2022, 40, 2960–2969.
  55. Tebas, P.; Yang, S.; Boyer, J.D.; et al. Safety and Immunogenicity of INO-4800 DNA Vaccine against SARS-CoV-2: A Preliminary Report of an Open-Label, Phase 1 Clinical Trial. eClinicalMedicine 2021, 31, 100689.
  56. Leung, N.H.L.; Cheng, S.M.S.; Cohen, C.A.; et al. Comparative Antibody and Cell-Mediated Immune Responses, Reactogenicity, and Efficacy of Homologous and Heterologous Boosting with CoronaVac and BNT162b2 (Cobovax): An Open-Label, Randomised Trial. Lancet Microbe 2023, 4, e670–e682.
  57. Alicandro, G.; Orena, B.S.; Rosazza, C.; et al. Humoral and Cell-Mediated Immune Responses to BNT162b2 Vaccine against SARS-CoV-2 in People with Cystic Fibrosis. Vaccine 2023, 41, 4114–4120.
  58. Fernández-Ciriza, L.; González, Á.; del Pozo, J.L.; et al. Humoral and Cellular Immune Response over 9 Months of mRNA-1273, BNT162b2 and ChAdOx1 Vaccination in a University Hospital in Spain. Sci. Rep. 2022, 12, 15606.
  59. Feng, Y.; Spezia, M.; Huang, S.; et al. Breast Cancer Development and Progression: Risk Factors, Cancer Stem Cells, Signaling Pathways, Genomics, and Molecular Pathogenesis. Genes Dis. 2018, 5, 77–106.
  60. Neal, L.; Tortorelli, C.L.; Nassar, A. Clinician’s Guide to Imaging and Pathologic Findings in Benign Breast disease. Mayo Clin. Proc. 2010, 85, 274–279.
  61. Dai, M.; Liu, D.; Liu, M.; et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020, 10, 783–791.
  62. Li, J.; Wang, H.; Geng, C.; et al. Suboptimal Declines and Delays in Early Breast Cancer Treatment after COVID-19 Quarantine Restrictions in China: A National Survey of 8397 Patients in the First Quarter of 2020. EClin.Med. 2020, 26, 100503.
  63. Zhang, S.; Li, J.; Xu, R.; et al. Safety of COVID-19 Vaccination in Patients with Breast Cancer: Cross-Sectional Study in China. JMIR Public Health Surveill. 2023, 9, e46009.
  64. Forster, M.; Wuerstlein, R.; Koenig, A.; et al. Health-Related Quality of Life and Patient-Centred Outcomes with COVID-19 Vaccination in Patients with Breast Cancer and Gynaecological Malignancies. Front. Oncol. 2023, 13, 1217805.
  65. Xu, Y.; Li, L.; Li, X.; et al. COVID-19 Vaccination Status, Side Effects, and Perceptions among Breast Cancer Survivors: A Cross-Sectional Study in China. Front. Public Health 2023, 11, 1119163.
  66. Jiang, Y.; Hou, L.; Mu, X.; et al. Willingness to Receive COVID-19 Vaccination and Adverse Effects after Vaccination in Breast Cancer Survivors during the COVID-19 Pandemic: A Cross-Sectional Retrospective Study of a Chinese Population. Ann. Transl. Med. 2023, 11, 56.
  67. De Placido, P.; Pietroluongo, E.; De Angelis, C.; et al. Safety and Immunogenicity of the COVID-19 vaccine BNT162b2 for Patients with Breast and Gynecological Cancer on Active Anticancer Therapy: Results of a Prospective Observational Study. Front. Oncol. 2022, 12, 951026.
  68. Joudi, M.; Moradi Binabaj, M.; Porouhan, P.; et al. A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome? Front. Endocrinol. (Lausanne) 2022, 13, 798975.
  69. Forster, M.; Wuerstlein, R.; Koenig, A.; et al. COVID-19 Vaccination in Patients with Breast Cancer and Gynecological Malignancies: A German Perspective. Breast 2021, 60, 214–222.
  70. Zagouri, F.; Terpos, E.; Fiste, O.; et al. SARS-CoV-2 Neutralizing Antibodies after First Vaccination dose in Breast Cancer Patients Receiving CDK4/6 Inhibitors. Breast 2021, 60, 58–61.
  71. Massarweh, A.; Eliakim-Raz, N.; Stemmer, A.; et al. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA Oncol. 2021, 7, 1133–1140.
  72. Addeo, A.; Shah, P.K.; Bordry, N.; et al. Immunogenicity of SARS-CoV-2 Messenger RNA Vaccines in Patients with Cancer. Cancer Cell 2021, 39, 1091–1098.
  73. Monin, L.; Laing, A.G.; Muñoz-Ruiz, M.; et al. Safety and Immunogenicity of One versus Two doses of the COVID-19 Vaccine BNT162b2 for Patients with Cancer: Interim Analysis of a Prospective Observational study. Lancet Oncol. 2021, 22, 765–778.
  74. Goshen-Lago, T.; Waldhorn, I.; Holland, R.; et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol. 2021, 7, 1507–1513.
  75. Palich, R.; Veyri, M.; Vozy, A.; et al. High Seroconversion rate but low Antibody Titers after Two Injections of BNT162b2 (Pfizer-BioNTech) Vaccine in Patients Treated with Chemotherapy for Solid Cancers. Ann. Oncol. 2021, 32, 1294–1295.
  76. Thakkar, A.; Gonzalez-Lugo, J.D.; Goradia, N.; et al. Seroconversion Rates Following COVID-19 Vaccination among Patients with Cancer. Cancer Cell 2021, 39, 1081–1090.e1082.
  77. Ehmsen, S.; Asmussen, A.; Jeppesen, S.S.; et al. Antibody and T Cell Immune Responses Following mRNA COVID-19 Vaccination in Patients with Cancer. Cancer Cell 2021, 39, 1034–1036.
  78. Malard, F.; Gaugler, B.; Gozlan, J.; et al. Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients with Hematologic Malignancies. Blood Cancer J. 2021, 11, 142.
  79. Van Oekelen, O.; Gleason, C.R.; Agte, S.; et al. Highly Variable SARS-CoV-2 Spike Antibody Responses to Two doses of COVID-19 RNA Vaccination in Patients with Multiple Myeloma. Cancer Cell 2021, 39, 1028–1030.
  80. Lim, S.H.; Campbell, N.; Johnson, M.; et al. Antibody Responses after SARS-CoV-2 Vaccination in Patients with Lymphoma. Lancet Haematol. 2021, 8, e542–e544.
  81. Pimpinelli, F.; Marchesi, F.; Piaggio, G.; et al. Fifth-Week Immunogenicity and Safety of anti-SARS-CoV-2 BNT162b2 Vaccine in Patients with Multiple Myeloma and Myeloproliferative Malignancies on Active Treatment: Preliminary Data from a Single Institution. J. Hematol. Oncol. 2021, 14, 81.
  82. Geisen, U.M.; Berner, D.K.; Tran, F.; et al. Immunogenicity and Safety of anti-SARS-CoV-2 mRNA Vaccines in Patients with Chronic Inflammatory Conditions and Immunosuppressive Therapy in a Monocentric Cohort. Ann. Rheum. Dis. 2021, 80, 1306–1311.
  83. Parry, H.; McIlroy, G.; Bruton, R.; et al. Antibody Responses after First and Second Covid-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia. Blood Cancer J. 2021, 11, 136.
  84. Molica, S.; Giannarelli, D.; Lentini, M.; et al. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study. Chemotherapy 2022, 67, 91–95.
  85. Lasagna, A.; Bergami, F.; Lilleri, D.; et al. Immunogenicity and Safety after the Third Dose of BNT162b2 Anti-SARS-CoV-2 Vaccine in Patients with Solid Tumors on Active Treatment: A Prospective Cohort Study. ESMO Open 2022, 7, 100458.
  86. Qin, K.; Honjo, K.; Sherrill-Mix, S.; et al. Exposure of Progressive Immune Dysfunction by SARS-CoV-2 mRNA Vaccination in Patients with Chronic Lymphocytic Leukemia: A Prospective Cohort Study. PLoS Med. 2023, 20, e1004157.
  87. Nyberg, T.; Ferguson, N.M.; Nash, S.G.; et al. Comparative Analysis of the Risks of Hospitalisation and Death Associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England: a Cohort Study. Lancet 2022, 399, 1303–1312.
  88. Menges, D.; Ballouz, T.; Anagnostopoulos, A.; et al. Burden of Post-COVID-19 Syndrome and Implications for Healthcare Service Planning: A Population-Based Cohort Study. PLoS One 2021, 16, e0254523.
  89. Cocchio, S.; Zabeo, F.; Tremolada, G.; et al. COVID-19 Vaccine Effectiveness against Omicron Variant among Underage Subjects: The Veneto Region’s Experience. Vaccines (Basel) 2022, 10, 1362.
  90. Bagherzadeh, M.A.; Izadi, M.; Baesi, K.; et al. Considering Epitopes Conservity in Targeting SARS-CoV-2 Mutations in Variants: A Novel Immunoinformatics Approach to Vaccine design. Sci. Rep. 2022, 12, 14017.
  91. Afkhami, S.; D’Agostino, M.R.; Zhang, A.; et al. Respiratory Mucosal Delivery of Next-Generation COVID-19 Vaccine Provides Robust Protection against Both Ancestral and Variant Strains of SARS-CoV-2. Cell 2022, 185, 896–915.
  92. Naz, A.; Shahid, F.; Butt, T.T.; et al. Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach. Front Immunol 2020, 11, 1663.
  93. Dar, H.A.; Waheed, Y.; Najmi, M.H.; et al. Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An In Silico Analysis. J. Immunol. Res. 2020, 2020, 8893483.
  94. Kombe Kombe, A.J.; Zahid, A.; Mohammed, A.; et al. Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection. Front. Mol. Biosci. 2021, 8, 670815.
  95. Barrière, J.; Chamorey, E.; Adjtoutah, Z.; et al. Impaired Immunogenicity of BNT162b2 Anti-SARS-CoV-2 Vaccine in Patients Treated for Solid Tumors. Ann. Oncol. 2021, 32, 1053–1055.
  96. Herishanu, Y.; Avivi, I.; Aharon, A.; et al. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia. Blood 2021, 137, 3165–3173.
  97. Maneikis, K.; Šablauskas, K.; Ringelevičiūtė, U.; et al. Immunogenicity of the BNT162b2 COVID-19 mRNA Vaccine and Early Clinical Outcomes in Patients with Haematological Malignancies in Lithuania: A National Prospective Cohort Study. Lancet Haematol. 2021, 8, e583–e592.
  98. Terpos, E.; Gavriatopoulou, M.; Ntanasis-Stathopoulos, I.; et al. The Neutralizing Antibody Response post COVID-19 Vaccination in Patients with Myeloma is Highly Dependent on the Type of Anti-Myeloma Treatment. Blood Cancer J. 2021, 11, 138.
  99. Houot, R.; Levy, R.; Cartron, G.; et al. Could Anti-CD20 Therapy Jeopardise the Efficacy of a SARS-CoV-2 Vaccine. Eur. J. Cancer 2020, 136, 4–6.
  100. Rasalkar, A.A.; Bhatia, S.; Katte, T.; et al. COVID-19 and its Impact on Cancer, HIV, and Mentally Ill Patients. Lessons from COVID-19. 2022, 95–137.
  101. Latif, M.B.; Shukla, S.; Del Rio Estrada, P.M.; et al. Immune Mechanisms in Cancer Patients that Lead to Poor Outcomes of SARS-CoV-2 Infection. Transl. Res. 2022, 241, 83–95.
  102. Arieta, C.M.; Xie, Y.J.; Rothenberg, D.A.; et al. The T-Cell-Directed Vaccine BNT162b4 Encoding Conserved Non-Spike Antigens Protects Animals from Severe SARS-CoV-2 Infection. Cell 2023, 186, 2392–2409.
  103. Malik, J.A.; Ahmed, S.; Mir, A.; et al. The SARS-CoV-2 Mutations versus Vaccine Effectiveness: New Opportunities to New Challenges. J. Infect. Public Health 2022, 15, 228–240.
  104. Nelde, A.; Rammensee, H.G.; Walz, J.S. The Peptide Vaccine of the Future. Mol. Cell. Proteom. 2021, 20, 100022.
  105. Coffman, R.L.; Sher, A.; Seder, R.A. Vaccine Adjuvants: Putting Innate Immunity to Work. Immunity 2010, 33, 492–503.
  106. Finn, O.J. Cancer Vaccines: Between the Idea and the Reality. Nat. Rev. Immunol. 2003, 3, 630–641.
  107. Nunès, J.A.; Wise-Draper, T.M.; Lambert, C. Editorial: The Relationship between COVID-19 Severity and Cancer Immunity and Immunotherapy. Front. Immunol. 2023, 14, 1184007.